This week, May Health’s Ovarian Rebalancing showed promise as a treatment for polycystic ovarian syndrome; a trial of CathWorks’ FFRangio System launched; Roche introduced new assays for Alzheimer’s Disease; Early Health settled data breach allegations; and Boston Scientific added two new board members.
Results from the ULTRA US and European feasibility trials showed May Health’s Ovarian Rebalancing is a promising treatment for women with endocrine disorder polycystic ovary syndrome (PCOS).
Ovarian Rebalancing is transvaginal ultrasound-guided ovarian ablation with May Health’s radiofrequency device